atropine has been researched along with candesartan in 4 studies
| Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) | Studies (candesartan) | Trials (candesartan) | Recent Studies (post-2010) (candesartan) |
|---|---|---|---|---|---|
| 26,711 | 1,259 | 1,697 | 1,929 | 412 | 589 |
| Protein | Taxonomy | atropine (IC50) | candesartan (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 3.2769 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 5.9472 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.0652 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 9 | |
| Adenosine receptor A3 | Homo sapiens (human) | 1.2199 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 3 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 4.3 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.843 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.0652 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.0594 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0405 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bivalacqua, TJ; Champion, HC; Dalal, A; Kadowitz, PJ | 1 |
| Dendorfer, A; Dominiak, P; Raasch, W; Ziegler, A | 1 |
1 review(s) available for atropine and candesartan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for atropine and candesartan
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Role of AT(1) receptors and autonomic nervous system in mediating acute pressor responses to ANG II in anesthetized mice.
Topics: Adrenergic beta-Antagonists; Anesthesia; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atropine; Autonomic Nervous System; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Enalaprilat; Heart Rate; Hexamethonium; Imidazoles; Mice; Mice, Inbred Strains; Parasympatholytics; Phentolamine; Propranolol; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Vascular Resistance; Vasoconstrictor Agents | 1999 |
Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation.
Topics: Adrenergic alpha-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Atropine; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Desipramine; Diastole; Dose-Response Relationship, Drug; Losartan; Male; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Propranolol; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-2; Reserpine; Sympathectomy, Chemical; Sympathetic Nervous System; Symporters; Tetrazoles; Tubocurarine; Yohimbine | 2004 |